Relapsing-remitting multiple sclerosis RRMS

Haas J (2003) Onset of clinical benefit of gladramer acetate (Copaxone) acetate in 255 patients widi relapsing remitting multiple sclerosis (RRMS). Neur-ol 60(suppl) P06-105. 

Interferon beta-lb is admini.stered SC to decrease the frequency of clinical exacerbation in ambulatory patients with relapsing-remitting multiple sclerosis (RRMS). RRMS is characterized by unpredictable attacks resulting in neurological deficits, separated by variable periods of remission. 

A study involving clinically stable patients witir relapsing-remitting multiple sclerosis (RRMS), 21 therapy-naive and 14 IFNp with a statin, showed that high-dose statin therapy significantly reduced IFNp fxmction and responses to type I IFNs in RRMS patients. These findings may be an indication of how statins impair the beneficial effects of IFNp and lead to worsened disease outcomes [bl" ]. 

---